Salvador, FernandoLucas-Dato, AnaRoure, SilviaArsuaga, MartaPérez-Jacoiste, AsunciónGarcía-Rodríguez, MagdalenaPérez-Molina, José ABuonfrate, DoraSaugar, Jose MariaMolina, Israel2022-04-182022-04-182021-06-27Pathogens. 2021;10(7):812.2076-0817http://hdl.handle.net/20.500.12105/13984Strongyloidiasis affects an estimated 600 million people worldwide, especially in tropical and subtropical areas. Single-dose ivermectin treatment has shown to be effective among immunocompetent patients with uncomplicated strongyloidiasis. Here, we present the protocol of the ImmunoStrong study, a prospective observational study aiming to evaluate the effectiveness and safety of a single-dose ivermectin for treatment of uncomplicated strongyloidiasis in immunosuppressed patients. The secondary objectives are to assess accuracy of molecular techniques for the follow-up of these patients and to determine the population pharmacokinetics of ivermectin. The information retrieved by this study will cover relevant information gaps in the strongyloidiasis management among immunosuppressed patients.engVoRhttp://creativecommons.org/licenses/by/4.0/PCRStrongyloides stercoralisImmunosuppressionIvermectinPopulation pharmacokineticsAtribución 4.0 Internacional3419900010781210.3390/pathogens10070812Pathogens (Basel, Switzerland)open access